These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 36257147)

  • 1. Targeting human thymidylate synthase: Ensemble-based virtual screening for drug repositioning and the role of water.
    Mteremko D; Chilongola J; Paluch AS; Chacha M
    J Mol Graph Model; 2023 Jan; 118():108348. PubMed ID: 36257147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finding alternatives to 5-fluorouracil: application of ensemble-based virtual screening for drug repositioning against human thymidylate synthase.
    Mteremko D; Shadrack DM; Ntie-Kang F; Chilongola J; Chacha M
    J Biomol Struct Dyn; 2023 Jul; 41(11):4873-4889. PubMed ID: 35538714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ensemble-based virtual screening of African natural products to target human thymidylate synthase.
    Mteremko D; Chilongola J; Paluch AS; Chacha M
    J Mol Graph Model; 2023 Dec; 125():108568. PubMed ID: 37591123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case.
    Siragusa L; Luciani R; Borsari C; Ferrari S; Costi MP; Cruciani G; Spyrakis F
    ChemMedChem; 2016 Aug; 11(15):1653-66. PubMed ID: 27404817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of potential inhibitors against FemX of Staphylococcus aureus: A hierarchial in-silico drug repurposing approach.
    Rahman S; Rajak K; Mishra S; Das AK
    J Mol Graph Model; 2022 Sep; 115():108215. PubMed ID: 35636337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease.
    Yuce M; Cicek E; Inan T; Dag AB; Kurkcuoglu O; Sungur FA
    Proteins; 2021 Nov; 89(11):1425-1441. PubMed ID: 34169568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep-learning based repurposing of FDA-approved drugs against
    Joshi T; Pundir H; Chandra S
    J Biomol Struct Dyn; 2022 Nov; 40(18):8420-8436. PubMed ID: 33879017
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performing an In Silico Repurposing of Existing Drugs by Combining Virtual Screening and Molecular Dynamics Simulation.
    Sohraby F; Bagheri M; Aryapour H
    Methods Mol Biol; 2019; 1903():23-43. PubMed ID: 30547434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of novel inhibitors for
    Khedrinia M; Aryapour H; Mianabadi M
    Drug Chem Toxicol; 2021 Sep; 44(5):470-479. PubMed ID: 31668098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing Drugs for Inhibition against ALDH2 via a 2D/3D Ligand-Based Similarity Search and Molecular Simulation.
    Jiang W; Chen J; Zhang P; Zheng N; Ma L; Zhang Y; Zhang H
    Molecules; 2023 Oct; 28(21):. PubMed ID: 37959744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
    Elzupir AO
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug repurposing for ligand-induced rearrangement of Sirt2 active site-based inhibitors via molecular modeling and quantum mechanics calculations.
    Bharadwaj S; Dubey A; Kamboj NK; Sahoo AK; Kang SG; Yadava U
    Sci Rep; 2021 May; 11(1):10169. PubMed ID: 33986372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.
    Pathak Y; Mishra A; Choudhir G; Kumar A; Tripathi V
    Pharmacol Rep; 2021 Jun; 73(3):926-938. PubMed ID: 33970450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiscale Virtual Screening Optimization for Shotgun Drug Repurposing Using the CANDO Platform.
    Hudson ML; Samudrala R
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33925237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risedronate and Methotrexate Are High-Affinity Inhibitors of New Delhi Metallo-β-Lactamase-1 (NDM-1): A Drug Repurposing Approach.
    Muteeb G; Alsultan A; Farhan M; Aatif M
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
    Talluri S
    Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure investigation, enrichment analysis and structure-based repurposing of FDA-approved drugs as inhibitors of BET-BRD4.
    Wakchaure P; Velayutham R; Roy KK
    J Biomol Struct Dyn; 2019 Aug; 37(12):3048-3057. PubMed ID: 30079805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico Screening of Potential Spike Glycoprotein Inhibitors of SARS-CoV-2 with Drug Repurposing Strategy.
    Wei TZ; Wang H; Wu XQ; Lu Y; Guan SH; Dong FQ; Dong CL; Zhu GL; Bao YZ; Zhang J; Wang GY; Li HY
    Chin J Integr Med; 2020 Sep; 26(9):663-669. PubMed ID: 32740825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.